Friday, June 03, 2016 4:04:51 PM
"It is easier to fool someone, than to convince them they have been fooled."
For those that don't get it, it means that people need to be more careful, and do good due diligence.
Recent ATOS News
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 05/10/2024 01:04:04 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/10/2024 01:00:05 PM
- Atossa Therapeutics Announces Support of New Breast Cancer Screening Guidelines • GlobeNewswire Inc. • 05/07/2024 12:30:00 PM
- Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Evaluate Synergy Between Antibody Drug Conjugates (ADCs) and (Z)-Endoxifen • GlobeNewswire Inc. • 04/29/2024 12:30:00 PM
- Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer • GlobeNewswire Inc. • 04/15/2024 12:30:00 PM
- Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference • GlobeNewswire Inc. • 04/11/2024 12:30:00 PM
- Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen • GlobeNewswire Inc. • 04/09/2024 03:59:00 PM
- Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 04/01/2024 08:00:00 PM
- Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for a U.S. Breast Cancer Patient • GlobeNewswire Inc. • 03/19/2024 12:30:00 PM
- Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements • GlobeNewswire Inc. • 03/18/2024 12:30:00 PM
- Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Directors • GlobeNewswire Inc. • 03/12/2024 12:30:00 PM
- Atossa Therapeutics Announces First Patient Dosing of (Z)-Endoxifen in the Ongoing RECAST DCIS Study • GlobeNewswire Inc. • 02/22/2024 01:30:00 PM
- Atossa Therapeutics Announces Full Enrollment of (Z)-Endoxifen Arm of I-SPY 2 Clinical Trial • GlobeNewswire Inc. • 02/07/2024 01:30:00 PM
- Atossa Therapeutics Issues Letter to Shareholders • GlobeNewswire Inc. • 01/09/2024 01:30:00 PM
- Atossa Therapeutics Announces the Appointment of Arezoo Mirad, M.D., as Senior Medical Director • GlobeNewswire Inc. • 12/04/2023 01:30:00 PM
- Atossa Therapeutics Announces Full Enrollment of Phase 2 Karisma-Endoxifen Clinical Trial • GlobeNewswire Inc. • 11/20/2023 01:30:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 11/15/2023 09:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/15/2023 09:05:28 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 02:10:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 02:00:13 PM
- Atossa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 11/13/2023 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 02:00:40 PM
- Atossa Therapeutics Appoints Financial Executive Jonathan Finn to its Board of Directors • GlobeNewswire Inc. • 11/09/2023 02:00:00 PM
- Quantum Leap Healthcare Collaborative Initiates Landmark Phase 2 RECAST DCIS Platform Trial to Evaluate Alternative DCIS Treatments with Atossa Therapeutics, Havah Therapeutics, and the Menarini Group • PR Newswire (US) • 10/30/2023 05:00:00 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM